Form 4: Zenas BioPharma Director Patrick Enright Granted 18,500 Stock Options

Zenas BioPharma, Inc. Director Patrick G. Enright was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Summary

• Patrick G. Enright, a Director of Zenas BioPharma, Inc. (ZBIO), was granted 18,500 stock options on June 10, 2025.
• The stock options have an exercise price of $11.94 per share.
• These options will vest as to 100% of the underlying shares of common stock on June 10, 2026, which is the first anniversary of the vesting commencement date.
• The vesting is subject to Mr. Enright's continued service with the company.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Mr. Enright beneficially owns 18,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While it's a routine compensation event and not a direct financial gain for the company, it signifies continued alignment of a director's interests with shareholder value and is a standard practice for incentivizing long-term commitment and performance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period (until June 10, 2035), providing a long window for potential value realization.

Negatives

• The options do not vest immediately, requiring continued service until June 10, 2026, for the director to fully realize the benefit.
• The value of the options is dependent on the future performance of Zenas BioPharma's stock price relative to the $11.94 exercise price.

Risks

• The primary risk is that the company's stock price may not exceed the exercise price of $11.94, rendering the options worthless.
• The vesting of the options is contingent upon the director's continued service, meaning forfeiture if service ceases before June 10, 2026.

Future Outlook

The grant of stock options to a director suggests a continued commitment to the company's long-term success and aligns the director's incentives with future shareholder value creation. The vesting schedule encourages retention of key personnel.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for directors and executives. It serves as a key component of compensation packages, aiming to attract, retain, and motivate talent by linking their financial success to the company's performance and stock appreciation.

Comparison to Industry Standards

• The structure of this equity grant, including the exercise price and vesting schedule, is consistent with typical compensation practices for directors in the biotech sector. While specific comparable companies or projects are not detailed in this Form 4, such grants are standard across companies like Moderna, BioNTech, or Regeneron, which frequently use stock options to incentivize long-term performance and align director interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options' value increases with the company's stock price, potentially leading to more focused efforts on long-term growth and profitability.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• Patrick G. Enright must continue his service with Zenas BioPharma, Inc. until June 10, 2026, for the granted stock options to fully vest.

Key Dates

Recommendation

Keywords

Zenas BioPharma, ZBIO, Form 4, Stock Option, Insider Transaction, Beneficial Ownership, Patrick Enright, Equity Compensation, Director Compensation